Comparison of the effectiveness of two medicines namely Methotrexate and Apremilast in patients with a skin disease called psoriasis

Comparison of the efficacy of Methotrexate (Mtx) and Apremilast (Apr) in psoriasis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018854

Enrollment

Registered

2019-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Methotrexate: An immunosuppressive drug approved for psoriasis. Methotrexate will be given in a dose of 7.5 mg per week orally for 4 months Control Intervention1: Apremilast: It is a ph

Eligibility

Inclusion criteria

Inclusion criteria: •All patients visiting the Dermatology OPD diagnosed to have Psoriasis who needs systemic therapy. •Patients requiring and willing to undergo treatment with Methotrexate or Apremilast

Exclusion criteria

Exclusion criteria: 1.Patients who have taken systemic therapy in past three months or topical treatment or phototherapy in past 2 weeks 2.Who are lesser than 18 years of age. 3.Pregnant or those having any serious illness contraindicating systemic therapy.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of Methotrexate and ApremilastTimepoint: 4 months	—

Secondary

Measure	Time frame
To compare the side effects of Methotrexate and ApremilastTimepoint: 4 months	—

Countries

India

Contacts

Public ContactDr Manjunath Shenoy M

Yenepoya Medical College

manjunath576117@yahoo.co.in9845009976

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026